This preprint is under consideration at Virology Journal. A preprint is a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
Research
Anıl Uçan
Ministry of Health
Corresponding Author
ORCiD: https://orcid.org/0000-0001-8771-6121
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Background: Although more than a year past since COVID-19 was defined, there is no specific treatment yet. Since COVID-19 management differs over time, it is hard to determine which therapy is more efficacious. In this study, we aimed to evaluate the efficacy of the regimen with Favipiravir (FPV) and determine if the timing of FPV addition offers any improvement.
Methods: A retrospective observational case-controlled cohort study was performed between March and Sep-tember 2020, including adults with COVID-19 in a single-center in Turkey. We categorized patients into age-sex matched three groups, group 1 (n=48) and group 2 (n=48) included patients treated with the combination of FPV plus Hydroxychloroquine (HQ) early and late, respectively. Group 3 (n=48) consisted of patients on HQ monot-herapy. In Group 2, if the respiratory or clinic condition had not improved sufficiently, FPV was added on or after day 3.
Results: We found that starting FPV early had an impact on PCR negativity and the progression of the disease. 'No progression' was defined as the absence of a new finding in the control radiological examination and the absence of accompanying clinical deterioration. Also, the decrease in C-reactive protein (CRP) was greater in Group 1 than Group 3 (p <0.001). However, we found that early initiation of FPV treatment did not have a posi-tive effect on the estimated survival time.
Conclusions: According to this retrospective study results, we believe that for better clinical outcomes, FPV treatment should be started promptly to enhance antiviral effects and improve clinical outcomes.
Keywords
Severe acute respiratory syndrome coronavirus 2, Pneumonia, Favipiravir, Hydroxychloroquine, Antiviral therapy
Figure 1
Figure 2
Loading...
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Under Review
Version (no preprint)
Posted 12 May, 2021
Editor assigned
On 11 May, 2021
Submission checks complete
On 11 May, 2021
Editor invited
On 11 May, 2021
This version was not preprinted
Version 1
Posted 04 Feb, 2021
Community comments: 1
Editorial decision: Minor revision
On 28 Apr, 2021
Reviewer #2 agreed
On 12 Mar, 2021
Review #2 received
Received 12 Mar, 2021
Review #1 received
Received 12 Mar, 2021
Reviewer #1 agreed
On 09 Mar, 2021
Reviews received
Received 09 Mar, 2021
Reviewers invited
Invitations sent on 06 Feb, 2021
Editor assigned
On 02 Feb, 2021
Editor invited
On 02 Feb, 2021
Submission checks complete
On 01 Feb, 2021
First submitted
On 27 Jan, 2021
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Subject Areas
Virology
Learn more about our company.
This preprint is under consideration at Virology Journal. A preprint is a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
Research
Anıl Uçan
Ministry of Health
Corresponding Author
ORCiD: https://orcid.org/0000-0001-8771-6121
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Under Review
Version (no preprint)
Posted 12 May, 2021
Editor assigned
On 11 May, 2021
Submission checks complete
On 11 May, 2021
Editor invited
On 11 May, 2021
This version was not preprinted
Version 1
Posted 04 Feb, 2021
Community comments: 1
Editorial decision: Minor revision
On 28 Apr, 2021
Reviewer #2 agreed
On 12 Mar, 2021
Review #2 received
Received 12 Mar, 2021
Review #1 received
Received 12 Mar, 2021
Reviewer #1 agreed
On 09 Mar, 2021
Reviews received
Received 09 Mar, 2021
Reviewers invited
Invitations sent on 06 Feb, 2021
Editor assigned
On 02 Feb, 2021
Editor invited
On 02 Feb, 2021
Submission checks complete
On 01 Feb, 2021
First submitted
On 27 Jan, 2021
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Subject Areas
Virology
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Background: Although more than a year past since COVID-19 was defined, there is no specific treatment yet. Since COVID-19 management differs over time, it is hard to determine which therapy is more efficacious. In this study, we aimed to evaluate the efficacy of the regimen with Favipiravir (FPV) and determine if the timing of FPV addition offers any improvement.
Methods: A retrospective observational case-controlled cohort study was performed between March and Sep-tember 2020, including adults with COVID-19 in a single-center in Turkey. We categorized patients into age-sex matched three groups, group 1 (n=48) and group 2 (n=48) included patients treated with the combination of FPV plus Hydroxychloroquine (HQ) early and late, respectively. Group 3 (n=48) consisted of patients on HQ monot-herapy. In Group 2, if the respiratory or clinic condition had not improved sufficiently, FPV was added on or after day 3.
Results: We found that starting FPV early had an impact on PCR negativity and the progression of the disease. 'No progression' was defined as the absence of a new finding in the control radiological examination and the absence of accompanying clinical deterioration. Also, the decrease in C-reactive protein (CRP) was greater in Group 1 than Group 3 (p <0.001). However, we found that early initiation of FPV treatment did not have a posi-tive effect on the estimated survival time.
Conclusions: According to this retrospective study results, we believe that for better clinical outcomes, FPV treatment should be started promptly to enhance antiviral effects and improve clinical outcomes.
Figure 1
Figure 2
Loading...